BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2021 11:20:59 AM | Browse: 851 | Download: 2507
 |
Received |
|
2021-03-19 03:36 |
|
Peer-Review Started |
|
2021-03-19 03:39 |
|
First Decision by Editorial Office Director |
|
2021-06-03 22:43 |
|
Return for Revision |
|
2021-06-03 22:43 |
|
Revised |
|
2021-06-04 14:43 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-06-22 14:12 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-06-22 14:34 |
|
Articles in Press |
|
2021-06-22 14:34 |
|
Edit the Manuscript by Language Editor |
|
2021-07-01 04:59 |
|
Typeset the Manuscript |
|
2021-07-21 12:43 |
|
Publish the Manuscript Online |
|
2021-07-26 11:20 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ting Liu, Xiao-Li Xie, Xue Zhou, Sheng-Xiong Chen, Yi-Jun Wang, Lin-Ping Shi, Shu-Jia Chen, Yong-Juan Wang, Shu-Ling Wang, Jiu-Na Zhang, Shi-Ying Dou, Xiao-Yu Jiang, Ruo-Lin Cui and Hui-Qing Jiang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
81770601 |
| National Natural Science Foundation of China |
81702324 |
| National Natural Science Foundation of China |
81602529 |
| Natural Science Foundation of Hebei Province |
H2018206176 |
| Natural Science Foundation of Hebei Province |
H2017206141 |
| Post-graduate’s Innovation Fund Project of Hebei Province |
CXZZBS2019121 |
|
| Corresponding Author |
Hui-Qing Jiang, MD, Professor, Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215 Heping West Road, Shijiazhuang 050000, Hebei Province, China. jianghq@aliyun.com |
| Key Words |
Y-box binding protein 1; Hepatocellular carcinoma; Sorafenib; Drug resistance; Phosphoinositide-3-kinase/protein kinase B |
| Core Tip |
Y-box binding protein 1 (YB-1) was significantly increased in hepatocellular carcinoma (HCC), and it could increase the IC50 values of sorafenib in HCC cell lines. Meanwhile, YB-1 suppressed apoptosis and cell proliferation inhibition induced by sorafenib. Furthermore, we screened the phosphoinositide-3-kinase (PI3K)/protein kinase B (Akt) signaling pathway to explore the molecular mechanism of sorafenib resistance by the KEGG pathway enrichment analysis of the digital gene expression profiling-seq. And the blockade of PI3K/Akt signaling pathway by LY294002 mitigated YB-1-induced sorafenib resistance. Given that sorafenib is the first-line treatment for patients with advanced HCC, we proposed that the down-regulation of YB-1 is of great significance for the application of sorafenib in advanced HCC. |
| Publish Date |
2021-07-26 11:20 |
| Citation |
Liu T, Xie XL, Zhou X, Chen SX, Wang YJ, Shi LP, Chen SJ, Wang YJ, Wang SL, Zhang JN, Dou SY, Jiang XY, Cui RL, Jiang HQ. Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma. World J Gastroenterol 2021; 27(28): 4667-4686
|
| URL |
https://www.wjgnet.com/1007-9327/full/v27/i28/4667.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v27.i28.4667 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
